Magapu Solomon Sudhakar

The Lymphatic Fluid and T-Cell Receptor Vβ expression in Peripheral Blood Mononuclear Cells (PBMCs) of patients with Wuchereria Bancrofti Infection

Doctoral Thesis / Dissertation

G R I N 🙂

YOUR KNOWLEDGE HAS VALUE



- We will publish your bachelor's and master's thesis, essays and papers
- Your own eBook and book sold worldwide in all relevant shops
- Earn money with each sale

Upload your text at www.GRIN.com and publish for free



Bibliographic information published by the German National Library:

The German National Library lists this publication in the National Bibliography; detailed bibliographic data are available on the Internet at http://dnb.dnb.de .

This book is copyright material and must not be copied, reproduced, transferred, distributed, leased, licensed or publicly performed or used in any way except as specifically permitted in writing by the publishers, as allowed under the terms and conditions under which it was purchased or as strictly permitted by applicable copyright law. Any unauthorized distribution or use of this text may be a direct infringement of the author s and publisher s rights and those responsible may be liable in law accordingly.

Imprint:

Copyright © 2006 GRIN Verlag ISBN: 9783656083665

This book at GRIN:

https://www.grin.com/document/183781

The Lymphatic Fluid and T-Cell Receptor Vβ expression in Peripheral Blood Mononuclear Cells (PBMCs) of patients with Wuchereria Bancrofti Infection

GRIN - Your knowledge has value

Since its foundation in 1998, GRIN has specialized in publishing academic texts by students, college teachers and other academics as e-book and printed book. The website www.grin.com is an ideal platform for presenting term papers, final papers, scientific essays, dissertations and specialist books.

Visit us on the internet:

http://www.grin.com/ http://www.facebook.com/grincom http://www.twitter.com/grin_com

ANTIGENIC ANALYSIS OF LYMPHATIC FLUID AND T-CELL RECEPTOR Vβ (1-24) REPERTOIRE GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCs) OF PATIENTS WITH CHRONIC PATHOLOGY HARBOURING *WUCHERERIA BANCROFTI* INFECTION

A THESIS

Submitted by

M. SOLOMON SUDHAKAR

in the fulfilment for the award of the degree

of

DOCTOR OF PHILOSOPHY



FACULTY OF SCIENCE AND HUMANITIES ANNA UNIVERSITY : CHENNAI – 600 025

DECEMBER 2006

ANNA UNIVERSITY : CHENNAI – 600 025

BONAFIDE CERTIFICATE

Certified that this thesis titled "ANTIGENIC ANALYSIS OF LYMPHATIC FLUID AND T-CELL RECEPTOR Vβ (1-24) **REPERTOIRE GENE EXPRESSION IN PERIPHERAL BLOOD** MONONUCLEAR CELLS (PBMCs) OF PATIENTS WITH HARBOURING **CHRONIC** PATHOLOGY **WUCHERERIA** BANCROFTI **INFECTION**" is the bonafide work of Mr. M. SOLOMON SUDHAKAR who carried out the research under my supervision. Certified further that to the best of my knowledge the work reported herein does not form part of any other thesis or dissertation on the basis of which a degree or award was conferred on an earlier occasion of this or any other candidate.

> Dr. R.B. NARAYANAN (SUPERVISOR) Professor and Director Centre for Biotechnology Anna University Chennai – 600 025.

ABSTRACT

Lymphatic filariasis (LF) is a disease that is currently the target of a major global initiative for elimination. During the past decade, both the treatment and the control strategies for LF have undergone major paradigm shifts – due to rapid increase in knowledge and understanding of LF, that is derived directly from a series of commendable progress made by scientific and medical research communities. As a result, a public health dimension with a focus on affected populations, now supplements the earlier, predominantly patient-oriented clinical approach to LF.

The Indian government launched a nationwide LF control programme with the components of transmission interruption by annual mass-drug therapy, using diethylcarbamazine with/without albendazole, and the alleviation of disability and suffering among affected people.

In pursuit of understanding such a disease to which a social stigma is attached, the chronic pathology of LF was taken as a model to understand the immunopathological mechanisms that lead to acute lymphangitis and lymphadenitis, in filarial infections, harboring *Wuchereria bancrofti*. Hence, an attempt was made in this thesis to identify parasite specific antigens and antibodies in lymphatic fluid, which accumulates in CP conditions. At the same time, the corresponding serum from the same patient who was suffering from chronic pathology of filariasis, was also taken for analysis. It is a well established fact that elephantiasis is a consequence of immune reactivity to adult worm antigens. Therefore, it was thought that T-cells infiltrating the lesions in chronic pathology disease, could augment for elevated inflammation seen in CP. An attempt was also made to examine T cell by TCR V β analysis using RT PCR and antigen stimulated PBMC's. Therefore, 24 V β gene families in the given repertoire was the choice for experimental analysis. Along with all CP cases for these studies in both the objectives, appropriate controls were also included in this study as EN, who are normal healthy individuals and MF, who are carriers of this disease. At the onset, it was thought that bacterial infections could predominate the sequence of infections in CP. As such, an attempt was also made to study the effect of lymphatic fluid on the bacterial growth *in vitro*, and the presence of antibodies against bacteria that cause secondary infections, was assessed.

Lymphatic fluid and corresponding serum contains parasite specific antigens and antibodies when analyzed by SDS-PAGE and Western blot. At the sametime, LF promoted the growth of *beta –hemolytic streptococci* bacteria which usually predominates the secondary infections. Specific T Cell Receptors which get overrepresented in the CP subjects when the PBMCs of these subjects come in contact with crude antigen of the parasite BmA but MF's, do not show any overrepresentation for BmA under similar conditions.

ACKNOWLEDGEMENT

I thank **Prof. R.B. Narayanan**, my mentor, for providing me with the opportunity to work on filarial chronic pathology for immunopathological studies. I thank **Prof. P. Kaliraj**, **Dr. V. Murugan** and **Dr. K. Sankaran** from the Centre for Biotechnology for providing me with the facilities available in their laboratories and their encouragement. I thank my Doctoral Committee Members **Dr. V. Kumaraswami** and **Dr. V.D. Ramanathan**, Deputy Directors from TRC, Chennai, for their valuable suggestions and sparing their valuable time to critically read the methods, results and discussion of my thesis.

I am grateful to **Prof. K.V. Alalasundaram** Head, Plastic Surgery Dept., Govt. Roypettah Hospital, Chennai, for providing me with lymphoedema cases. I also thank **Dr. Dhanaraj** of Municipal Corp., Chennai, for mobilizing Microfilaraemics. I thank **Dr. S.V. Chiplunkar**, Head, Immunology Division ACTREC, TMH, Mumbai for training me in T-cell Receptor studies. I thank **Dr. M. Chandy**, Head, Hematology Dept., CMC, Vellore, for permitting me to work in his lab. I also thank **Dr. Rama Raja Ram**, HOD, Biochemistry Dept., CLRI, Chennai, for allowing me to carry out proliferation studies. I thank **Dr. R. Kirubagaran**, Scientist-E NIOT, Govt. of India, and **Dr. B. Nagarjan** HOD, Microbiology Dept., Cancer Institute, Chennai, for perusing my thesis and their suggestions. I thank **Dr. R. Ravanan**, Reader Dept of Statistics Presidency College, Chennai, for his statistical analyses. I express my gratitude to **LTMT**, Mumbai for awarding SRF for 2 years. I thank my father **Dr. M. Bhaskara Rao**, for his moral encouragement and financial support for the last six years. I thank all my friends for their sincere support.

MAGAPU SOLOMON SUDHAKAR

TABLE OF CONTENTS

CHAPTER	NO.		r	FITLE	PAGE NO.
	ABS	FRAC	Г		iii
	LIST	OF T	ABLES		xiii
	LIST	OF FI	GURES		XV
	LIST	OF A	BBREVI	IATIONS	xviii
1	INTI	RODU	CTION		
	1.1			OF THE THESIS	4
	1.2	OBJE	CTIVES		8
	1.3	REVI	EW OF 1	LITERATURE	10
		1.3.1	Filarial	Parasites	10
		1.3.2	Life Cy	cle	10
		1.3.3	Geogra	phic Distribution of	
			Filarial	Parasites	12
		1.3.4	Periodi	city	12
		1.3.5	Vectors	5	14
		1.3.6	Clinical	l Groups in Filariasis	14
			1.3.6.1	Asymptomatic amicrofilarem	ics
				(Endemic Normals)	15
			1.3.6.2	Asymptomatic	
				microfilaremics (MF)	15
			1.3.6.3	Chronic Pathology	15
			1.3.6.4	Non-filarial elephantiasis	16
			1.3.6.5	Tropical pulmonary	
				eosinophilia (TPE)	16

PAGE NO.

1.3.8.2Currently available vaccines181.3.8.3DNA vaccines191.3.8.4Potential vaccine candidates from <i>B. malayi</i> 191.3.8.5Adjuvants201.3.8.6Animal models in lymphatic filariasis211.3.9Diagnosis of lymphatic filariasis211.3.9.1Parasitological diagnosis211.3.9.2Lymphatic filariasis211.3.9.3Lymphagiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10.1Lymphoedema291.3.10.2Lymphoedema291.3.10.3Lymphoedema in conditions other than Filariasis301.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37	1.3.7	Filarial	Genome Project	16		
1.3.8.2Currently available vaccines181.3.8.3DNA vaccines191.3.8.4Potential vaccine candidates from <i>B. malayi</i> 191.3.8.5Adjuvants201.3.8.6Animal models in lymphatic filariasis211.3.9Diagnosis of lymphatic filariasis211.3.9.1Parasitological diagnosis211.3.9.2Lymphatic filariasis211.3.9.3Lymphagiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10.1Lymphoedema291.3.10.2Lymphoedema291.3.10.3Lymphoedema in conditions other than Filariasis301.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37	1.3.8	Vaccine for Filariasis				
1.3.8.3DNA vaccines191.3.8.4Potential vaccine candidates from <i>B. malayi</i> 191.3.8.5Adjuvants201.3.8.6Animal models in lymphatic filariasis211.3.9Diagnosis of lymphatic filariasis211.3.9.1Parasitological diagnosis211.3.9.2Lymphatic filariasis211.3.9.3Lymphatic imaging221.3.9.4DNA based diagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema in conditions other than Filariasis301.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.7Surgical treatment37		1.3.8.1	Need for the vaccine	17		
1.3.8.4Potential vaccine candidates from <i>B. malayi</i> 191.3.8.5Adjuvants201.3.8.6Animal models in lymphatic filariasis211.3.9Diagnosis of lymphatic filariasis211.3.9.1Parasitological diagnosis211.3.9.2Lymphatic filariasis211.3.9.3Lymphatic imaging221.3.9.4DNA based diagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema Mechanism of Formation291.3.10.3Lymphoedema in conditions other than Filariasis301.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37		1.3.8.2	Currently available vaccines	18		
from B. malayi 19 1.3.8.5 Adjuvants 20 1.3.8.6 Animal models in lymphatic filariasis 21 1.3.9 Diagnosis of lymphatic filariasis 21 1.3.9 Diagnosis of lymphatic filariasis 21 1.3.9 Parasitological diagnosis 21 1.3.9.1 Parasitological diagnosis 21 1.3.9.2 Lymphatic imaging 22 1.3.9.3 Lymphangiography 22 1.3.9.4 DNA based diagnosis 23 1.3.9.5 Immunodiagnosis 23 1.3.10 Lymph (Formation, Absorption and Flow) 27 1.3.10.1 Lymphoedema 29 1.3.10.2 Lymphoedema Mechanism 29 1.3.10.3 Lymphoedema in conditions other than 29 1.3.10.4 Stages of lymphoedema 31 1.3.10.5 Treatment of lymphoedema 31 1.3.10.6 Treatment of Filariasis 34 1.3.10.7 Surgical treatment 37		1.3.8.3	DNA vaccines	19		
1.3.8.5 Adjuvants201.3.8.6 Animal models in lymphatic filariasis211.3.9 Diagnosis of lymphatic filariasis211.3.9 Diagnosis of lymphatic filariasis211.3.9.1 Parasitological diagnosis211.3.9.2 Lymphatic imaging221.3.9.3 Lymphangiography221.3.9.4 DNA based diagnosis231.3.9.5 Immunodiagnosis231.3.10 Lymph (Formation, Absorption and Flow)271.3.10.1 Lymphoedema291.3.10.2 Lymphoedema Mechanism of Formation291.3.10.3 Lymphoedema in conditions other than Filariasis301.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37		1.3.8.4	Potential vaccine candidates			
1.3.8.6Animal models in lymphatic filariasis211.3.9Diagnosis of lymphatic filariasis211.3.9Diagnosis of lymphatic filariasis211.3.9.1Parasitological diagnosis211.3.9.2Lymphatic imaging221.3.9.3Lymphangiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema Mechanism291.3.10.3Lymphoedema in conditions other than Filariasis301.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37			from <i>B. malayi</i>	19		
lymphatic filariasis211.3.9Diagnosis of lymphatic filariasis211.3.9.1Parasitological diagnosis211.3.9.2Lymphatic imaging221.3.9.3Lymphangiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema Mechanism291.3.10.3Lymphoedema in conditions other than291.3.10.4Stages of lymphoedema311.3.10.5Treatment of Filariasis301.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37		1.3.8.5	Adjuvants	20		
1.3.9Diagnosis of lymphatic filariasis211.3.9Parasitological diagnosis211.3.9.1Parasitological diagnosis211.3.9.2Lymphatic imaging221.3.9.3Lymphangiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema291.3.10.3Lymphoedema in conditions other than Filariasis301.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37		1.3.8.6	Animal models in			
1.3.9.1Parasitological diagnosis211.3.9.2Lymphatic imaging221.3.9.3Lymphangiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema Mechanism291.3.10.3Lymphoedema in conditions other than Filariasis301.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37			lymphatic filariasis	21		
1.3.9.2Lymphatic imaging221.3.9.3Lymphangiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema Mechanism291.3.10.3Lymphoedema in291.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37	1.3.9	Diagnos	sis of lymphatic filariasis	21		
1.3.9.3Lymphangiography221.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema291.3.10.2Lymphoedema Mechanism291.3.10.3Lymphoedema in291.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37		1.3.9.1	Parasitological diagnosis	21		
1.3.9.4DNA based diagnosis231.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema Mechanism291.3.10.3Lymphoedema Mechanism291.3.10.3Lymphoedema in conditions other than Filariasis301.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37		1.3.9.2	Lymphatic imaging	22		
1.3.9.5Immunodiagnosis231.3.10Lymph (Formation, Absorption and Flow)271.3.10.1Lymphoedema291.3.10.2Lymphoedema Mechanism291.3.10.2Lymphoedema Mechanism291.3.10.3Lymphoedema in conditions other than291.3.10.4Stages of lymphoedema311.3.10.5Treatment of lymphoedema311.3.10.6Treatment of Filariasis341.3.10.7Surgical treatment37		1.3.9.3	Lymphangiography	22		
1.3.10 Lymph (Formation, Absorption and Flow)271.3.10.1 Lymphoedema291.3.10.2 Lymphoedema Mechanism291.3.10.2 Lymphoedema Mechanism291.3.10.3 Lymphoedema in conditions other than291.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37		1.3.9.4	DNA based diagnosis	23		
1.3.10.1 Lymphoedema291.3.10.2 Lymphoedema Mechanismof Formationof Formation291.3.10.3 Lymphoedema in conditions other than Filariasis301.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37		1.3.9.5	Immunodiagnosis	23		
1.3.10.2 Lymphoedema Mechanism of Formation291.3.10.3 Lymphoedema in conditions other than Filariasis301.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37	1.3.10	Lymph	(Formation, Absorption and Flow)	27		
of Formation291.3.10.3 Lymphoedema in conditions other than30Filariasis301.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37		1.3.10.1	Lymphoedema	29		
1.3.10.3 Lymphoedema in conditions other than Filariasis301.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37		1.3.10.2	2 Lymphoedema Mechanism			
conditions other thanFilariasis301.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37			of Formation	29		
Filariasis301.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37		1.3.10.3	B Lymphoedema in			
1.3.10.4 Stages of lymphoedema311.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37			conditions other than			
1.3.10.5 Treatment of lymphoedema311.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37			Filariasis	30		
1.3.10.6 Treatment of Filariasis341.3.10.7 Surgical treatment37		1.3.10.4	Stages of lymphoedema	31		
1.3.10.7 Surgical treatment37		1.3.10.5	5 Treatment of lymphoedema	31		
6		1.3.10.6	6 Treatment of Filariasis	34		
1.3.11 Immunity to Filariasis 37		1.3.10.7	7 Surgical treatment	37		
	1.3.11	Immuni	ity to Filariasis	37		

PAGE NO.

		1.3.11.1 Role of lymphocytes,	
		antigen presenting cells and	
		other cells in Filariasis	37
		1.3.11.2 Role of Cytokines in Filariasis	48
		1.3.11.3 Receptor signaling in Filariasis	52
		1.3.11.4 Antibody Responses in	
		Filarial infections	54
		1.3.11.5 Filarial antigens	57
	1.3.12	A Prelude to T-Cell Receptors (TCR'S)	58
		1.3.12.1 Gene Organization TCR	62
		1.3.12.2 TCR diversity	64
		1.3.12.3 Association of TCR	
		with CD3 complex	65
		1.3.12.4 TCR and Trimolecular	
		Complex	66
		1.3.12.5 T-Cell activation	70
	1.3.13	MHC recognition in filariasis	73
	1.3.14	T-Cell Receptor Studies in	
		Disease pathogenesis	74
2 MAT	ERIA	LS AND METHODS	
2.1	LYM	PHATIC FLUID ANALYSIS	76
	2.1.1	Study Population	76
	2.1.2	Sample Collection	76
		2.1.2.1 Protein Estimation	77
	2.1.3	Preparation of Parasite Antigens	78
		2.1.3.1 Preparation of Brugia malayi	
		(BmA) and Setaria digitata (SD)	

total crude extracts

PAGE NO.

ix

	2.1.3.2	Excretory Secretory Antigens	79
2.1.4	Product	ion of Antisera	79
	2.1.4.1	Animals Used	79
	2.1.4.2	Mice	79
	2.1.4.3	Rabbit	80
	2.1.4.4	Determination of titers	
		of anti-BmA and anti-ES	
		antibodies using ELISA	81
2.1.5	Identifi	cation, Characterization	
	of Antig	gens and Antibodies in	
	Lympha	atic fluid and Serum from	
	Patients	with Chronic Pathology	82
	2.1.5.1	Antisera	82
	2.1.5.2	SDS-Polyacrylamide Gel	
		Electrophoresis	82
	2.1.5.3	Western blot analysis of	
		lymphatic fluid and serum	
		of CP patients	83
	2.1.5.4	Isolation of Circulating	
		Immune Complex (CIC) from	
		CP patients	85
2.1.6	Second	ary Bacterial Infections	
	in Chro	nic Pathology Patients	85
	2.1.6.1	Bacterial strains used	
		in this study	85
	2.1.6.2	Culture Media	86
	2.1.6.3	ELISA	86
	2.1.6.4	Biological Effects of	
		Lymphatic fluid	87

CHAPTER NO.

2.2	T-CE	LL BETA	A VARIABLE RECEPTORS				
	Of 1-2	Of 1-24 GROUPS IN PATIENTS					
	WITH W. BANCROFTI INFECTION						
	2.2.1	Donors		88			
	2.2.2	Antiger	as and Mitogens	89			
	2.2.3	T-Cell	Receptor Beta Variable Primers	89			
	2.2.4	Beta Actin Primers as					
		Positive	e Controls	89			
	2.2.5	Cellula	Cellular Responses to Filarial				
		Antiger	ns <i>Brugia malayi</i> antigen				
		(BmA-	Crude Extract) and				
		Non-Fi	larial Antigen Purified Protein				
		Derivat	ive (PPD)	91			
		2.2.5.1	Lymphocyte Responses	91			
	2.2.6	Reverse Transcription-Polymerase					
		Chain F	Reaction (RT-PCR)	93			
		2.2.6.1	Extraction of RNA	93			
		2.2.6.2	Reverse transcription				
			reaction	95			
		2.2.6.3	PCR Amplifications				
			of cDNAs	98			
2.3	STAT	TISTICA	L ANALYSIS	102			

3 **RESULTS**

3.1	LYM	PHATIC FLUID ANALYSIS	103
	3.1.1	Study Population	103
	3.1.2	Sample Collection	103
	3.1.3	Production of Antisera	104

3.2

	3.1.3.1	Determination of the titers	
		of rabbit polyclonal anti-BmA	
		antibodies and mice polyclonal	
		anti-ES antibodies	105
3.1.4	Identifi	cation, Characterization of	
	Antiger	ns and Antibodies in	
	Lympha	atic fluid and Serum	
	from Cl	hronic Pathology Patients	105
	3.1.4.1	SDS-Polyacrylamide	
		gel electrophoresis	105
	3.1.4.2	Western blot analysis of	
		Lymphatic Fluid and Serum	
		of CP Patients	105
	3.1.4.3	Parasite antigens identified	
		in the Immune Complexes (I/C)	
		from serum of filarial patients	109
3.1.5	Second	ary Bacterial Infections	
	in Chro	nic Pathology Patients	112
	3.1.5.1	Reactivity of the lymphatic	
		fluid and serum with	
		Staphylococcus aureus and	
		α, β- hemolytic Streptococci	112
	3.1.5.2	ELISA	112
T-CE	LL BETA	A VARIABLE RECEPTORS	
OF 1-	24 GRO	UPS, IN PATIENTS	
WITH	I W. BAN	<i>VCROFTI</i> INFECTION	114
3.2.1	Donors		114
3.2.2	Cellula	r Responses	116

NO.	Т	TITLE	PAGE NO.
	3.2.2.1	Lymphocyte Cultures for	
		T-Cell Receptor Repertoire	
		Expressions	116
DIS	CUSSION		
4.1	WESTERN BL	OT ANALYSIS OF	
	LYMPHATIC	FLUID AND SERUM	
	OF CP PATIEN	NTS AND	
	BACTERIOLO	OGICAL STUDIES	141
4.2	TCR BETA VA	ARIABLE GENE	147
4.3	CONCLUSION	NS	155
4.4	FUTURE STU	DIES	157
APF	PENDIX 1		159
REF	FERENCES		163
LIS	Г OF PUBLICA	TIONS	204
VIT	AE		205

CHAPTER NO.

4

LIST OF TABLES

TABLE NO.TITLEPAGE NO.

1.1	State Wise Distribution of Filarial Endemic	
	Regions in India	13
1.2	Classification of Filarial Lymphoedema	32
2.1	TCR V β Primers	90
3.1	Demographic details of study population	
	for Lymphatic Fluid Analysis	104
3.2	Triglycerides profile and Protein Concentration in	
	the Pooled Lymphatic fluid and Serum of CP	104
3.3	Parasite antigens in the lymphatic fluid	
	and serum of CP patients identified	
	using Anti-BmA and Anti-ES antibodies	107
3.4	Parasite antigens identified by Western blot	
	using Lymphatic fluid and Serum of CP patients	
	as source of antibodies and S. digitata as antigen	109
3.5	Parasite antigens in the Serum Immune	
	complexes of the filarial patients identified	
	using Anti-BmA and Anti-ES	110
3.6	Effect of Lymphatic Fluid on the Growth	
	of Beta Hemolytic Streptococci	112
3.7	Demographic details of study population	
	for T Cell Receptors Repertoire	115
3.8	ANOVA for Significant Difference between	
	Genes for Each Stimulant in EN	121

xiii

TABLE NO.

PAGE NO.

3.9	ANOVA for Significant Difference between	
	Stimulants for Each TCRBV 1-24 Genes in EN	122
3.10	Comparative Analysis and Statistical	
	Significance of Gene Expressions in EN	123
3.11	ANOVA for Significant Difference	
	between TCRBV 1-24 Genes for	
	Each Stimulants in CP	127
3.12	ANOVA for Significant Difference	
	between Stimulants for Each TCRBV	
	1-24 Genes in CP	128
3.13	Comparative Analysis and Statistical	
	Significance of Gene Expressions in CP	129
3.14	ANOVA for Significant Difference between	
	Genes for Each Stimulant for MF	134
3.15	ANOVA for Significant Difference between	
	Stimulants for Each TCRBV 1-24 Genes for MF	135
3.16	Comparative Analysis and Statistical	
	Significance of Gene Expressions in MF	136

LIST OF FIGURES

FIGURE NO.

TITLE

PAGE NO.

1.1	Life Cycle of Wuchereria bancrofti	11
1.2	Areas endemic for lymphatic filariasis	13
1.3	Four major stages of Lymphoedema	33
1.4	Pneumatic Compression Treatment	
	for Filarial CP	35
1.5	Molecular structure of the TCR	60
1.6	Some members of the Ig-gene superfamily	
	of surface glycoproteins	61
1.7	Organization of human germline and	
	rearranged TCR genes	63
1.8	Class I MHC Molecular Structure	67
1.9	Class II MHC Molecular Structure	69
1.10	T-cell activation	71
2.1	Immunization and bleeding schedule	
	for polyclonal antibodies production for	
	ES antigens similar schedule was also	
	adopted for BmA antigen (crude extract)	80
3.1	SDS-PAGE of lymphatic fluid (A) and	
	serum (B) on 15% gel	106
3.2	Western blot analysis of pooled Lymphatic	
	fluid and Serum of CP patients	108
3.3	Western blot analysis of Immune complexes	
	of EN, MF and CP probed with anti-ES	111

FIGURE NO.

PAGE NO.

3.4 Western Blot of Immune Complexes from EN, MF and CP Probed with anti-BmA antiserum 111 3.5 Total IgG against S. aureus, alpha and beta-hemolytic Streptococci in the lymphatic fluid and serum of CP patients measured by ELISA. Horizontal bar shows the average value 113 3.6 A Profile of Total RNA obtained from PBMC's (5×10^6) of Endemic Normal. 5 µg/ml of RNA was taken for cDNA synthesis 117 3.6 B Profile of cDNA obtained from Total RNA (5 µg/ml) of PBMC's of EN 1 and 2 Samples converted by SuperScript[™] First-Strand Synthesis System for RT-PCR kit and run in the 2% agarose gel 117 3.7 Beta-Actin of 202 bp amplified by the cDNA and constructed by SuperScriptTM First-Strand Synthesis System for RT-PCR kit 118 3.8 Statistically Significant Stimulants in EN and TCRBV1-24 Profile Percentage Expression 124 3.9 TCRBV1-24 Profile for various cDNA of Endemic Normal (EN) 125 3.10a Statistically Significant Stimulant (PHA) CP and TCRBV1-24 Profile Percentage Expression 130 3.10b Statistically Significant Stimulant (BmA) CP and TCRBV1-24 Profile Percentage Expression 131

137

FIGURE NO.TITLEPAGE NO.3.11TCRBV1-24 Profile for various cDNA
of Chronic Pathology Patient1323.12Statistically Significant Stimulants in
MF and TCRBV1-24 Profile Percentage132

3.13	TCRBV1-24 Profile of Microfilaraemic Patient	138

Expression

LIST OF ABBREVIATIONS

μg	-	Microgram
μL	-	Microliter
ADL	-	Acute Adenolymphangitis
Ag	-	Antigen
ALP	-	Alkaline Phosphatase
ANOVA	-	Analysis Of Variance
Anti-BmA	-	Polyclonal antibodies raised against Brugia malayi adult
		antigen crude extract
Anti-ES	-	Polyclonal Antibodies Raised Against Excretory And
		Secretory Antigens
BCIP	-	Bromochloro Indole Phosphate
BmA	-	Brugia malayi Adult Antigen Crude Extract
bp	-	Base Pairs
BSA PBS	-	Bovine Serum Albumin In Phosphate Buffer Saline
BSA	-	Bovine Serum Albumin
cDNA	-	Complementary DNA
CDR3	-	Complementary Determining Region 3
CHISAM	-	Chloroform Isoamyl Alcohol Mix
CIC	-	Circulating Immune Complex
СР	-	Chronic Pathology
cRPM1640	-	Complete Roswell Park Memorial Institute 1640
		Medium
DEC	-	Diethyl Carbamazine
DEPC	-	Diethylpyrocabonate
dNTP	-	Deoxy Nucleotide Triphosphate

EDTA	-	Ethylene Diamine Tetra Acetic Acid
EGTA	-	Ethylene Glycol Tetra Acetic Acid
ELISA	-	Enzyme Linked Immunosorbo Assay
EN	-	Endemic Normal
FCS	-	Fetal Calf Serum
g	-	Gravity
IDV	-	Integrated Density Value
kD	-	Kilo Dalton
LF	-	Lymphatic filariasis
LSM	-	Lympho Separation Medium
MF	-	Microfilaremics
mf	-	Microfilariae
MOPS	-	3-(N-Morpholino) Propanesulfonic Acid
NBT	-	Nitro Blue Tetrazolium
NCP	-	Nitrocellulose Membrane
NEN	-	Non Endemic Normal
ng	-	Nanogram
nM	-	Nanomoles
NMS	-	Normal Mouse Serum
NRS	-	Normal Rabbit Serum
OD	-	Optical Density
PBMCs	-	Peripheral Blood Mononuclear Cells
PBST	-	Phosphate Buffer Saline Tween 20 (0.05%)
PEG	-	Polyethylene Glycol
PHA	-	Phytohaemagglutinin
pМ	-	Pico mole
PMSF	-	Phenyl Methyl Sulphonyl Fluoride
pNPP	-	Para Nitro Phenyl Phosphate
PPD	-	Purified Protein Derivative of Mycobacterium tuberculin
RPMI1640	-	Roswell Park Memorial Institute 1640 Medium